Allena Pharmaceuticals In... (ALNA)
Allena Pharmaceuticals Statistics
Share Statistics
Allena Pharmaceuticals has 0 shares outstanding. The number of shares has increased by 86.73% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | 86.73% |
| Shares Change (QoQ) | 26.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 120.96M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.58 and the forward PE ratio is null. Allena Pharmaceuticals's PEG ratio is -0.29.
| PE Ratio | -0.58 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.02 |
| P/FCF Ratio | -0.42 |
| PEG Ratio | -0.29 |
Enterprise Valuation
Allena Pharmaceuticals has an Enterprise Value (EV) of -10.2M.
| EV / Sales | 0 |
| EV / EBITDA | 0.32 |
| EV / EBIT | 0.22 |
| EV / FCF | 0.22 |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.11 |
| Quick Ratio | 2.11 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.01 |
| Interest Coverage | -63.4 |
Financial Efficiency
Return on Equity is -176.78% and Return on Invested Capital is -169.31%.
| Return on Equity | -176.78% |
| Return on Assets | -95.97% |
| Return on Invested Capital | -169.31% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.78M |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 510K |
| Effective Tax Rate | -1.55% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.15, so Allena Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.14 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 30.56 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -32.34M |
| Net Income | -33.35M |
| EBITDA | -31.97M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.03 |
Balance Sheet
The company has 29.99M in cash and 527K in debt, giving a net cash position of 29.46M.
| Cash & Cash Equivalents | 29.99M |
| Total Debt | 527K |
| Net Cash | 29.46M |
| Retained Earnings | -246.45M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -45.68M and capital expenditures -667K, giving a free cash flow of -46.34M.
| Operating Cash Flow | -45.68M |
| Capital Expenditures | -667K |
| Free Cash Flow | -46.34M |
| FCF Per Share | -1.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -173.18% |
| FCF Yield | -240.63% |
Analyst Forecast
Currently there are no analyst rating for ALNA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |